Clarus Therapeutics Holdings, Inc. (CRXTQ)의 가격은 얼마입니까?

Clarus Therapeutics Holdings, Inc. (CRXTQ)의 가격은 $0.0014입니다.

Clarus Therapeutics Holdings, Inc. (CRXTQ)의 시가 총액은 무엇입니까?

Clarus Therapeutics Holdings, Inc. (CRXTQ)의 시가 총액은 $72.83K입니다.

Clarus Therapeutics Holdings, Inc. (CRXTQ) 배당금

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

연도	배당금 (주식 분할 조정됨)	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금 (주식 분할 조정됨)

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도	배당금	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당금

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	배당 지급 횟수	국가
Eli Lilly and Company LLY.US	215.00%	US
Johnson & Johnson JNJ.US	225.00%	US
AbbVie Inc. ABBV.US	53.00%	US
Roche Holding AG RO.SW	33.00%	CH
Merck & Co., Inc. MRK.US	223.00%	US

회사

배당 지급 횟수

국가